In March 2025, the company declared new options for any direct-to-consumer presenting of its Wegovy weight loss drug. The company established a fresh pharmacy, named NovoCare, which might cost buyers $499 every month for use of the drug, below 50 percent the expense of the drug as a result of other pharmaceutical distribution networks.[fifty three]